Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Trial to Evaluate the Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations Under Fasted and Fed Conditions in Healthy Participants

NCT05106309 is registered in ClinicalTrials.gov with Cerevel Therapeutics, LLC as lead sponsor.

NCT NCT05106309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05106309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Trial to Evaluate the Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations Under Fasted and Fed Conditions in Healthy Participants
Lead sponsor
Cerevel Therapeutics, LLC
Phase
Phase 1
Overall status
Completed
Start date
December 29, 2021
Completion date
February 24, 2022
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia